Drug intelligence / Profile preview

CTX611

Development stage: Phase 1
Lead developer: CRISPR Therapeutics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

CTX611 is a small interfering RNA (siRNA) therapy under co-development by CRISPR Therapeutics and Sirius Therapeutics. This drug is designed to target Factor XI (FXI) and is being investigated for its potential in treating thromboembolic disorders. The collaboration, established in 2025, involves equal sharing of development costs and profits, with CRISPR Therapeutics leading commercialization efforts in the U.S. and Sirius Therapeutics overseeing commercialization in Greater China.

Targets

F11 (Coagulation Factor XI)

Beyond the preview

Go deeper on CTX611.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTX611.